Skip to main content
Premium Trial:

Request an Annual Quote

Digene Receives FDA Approval for Gene Probe Manufacturing Facility



AITHERSBURG, Md.--Digene has received approval from the US Food and Drug Administration to manufacture and distribute products of its Hybrid Capture Gene Analysis System at the company's new manufacturing, research, and development, and headquarters here. The approval covers the Digene Hybrid Capture II HPV Test for cervical cancer screening. The new facility was designed for high volume manufacturing of the company's gene analysis tests. Digene develops, manufactures, and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. The company has developed and is commercializing its patented Hybrid Capture Gene Analysis System and tests in three areas: women's cancers and infectious diseases, blood viruses, and pharmacogenomics.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.